New Biosimilar Approval Pathway Creates Device Opportunities
This article was originally published in The Gray Sheet
A new abbreviated regulatory pathway established by Congress for the approval of off-patent recombinant protein therapeutics could open up U.S. market opportunities for injection device technology firms
You may also be interested in...
Human factors engineering has gained traction in the device industry in recent years, but Richmond-based Intelliject is a rare example of a firm trying to build a business around a focus on product usability
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker